TRPM4 in Bladder Cancer: Prognostic Gene Risk Model and Drug Sensitivity

A study by Qi Zhao, integrating single-cell and whole-genome transcriptomic data, identified 220 candidate genes and a six-gene risk model for bladder cancer prognosis. The dataset includes results from immune infiltration analysis of 12 cell types and drug sensitivity analysis for 112 compounds. The file was last updated on 2026-04 13.

Use Cases

• Validating the six-gene prognostic risk model (UNC93B1, FAM193B, POGLUT3, FBN1, MAP1B, RUNX2) in independent bladder cancer cohorts.
• Analyzing immune cell infiltration patterns based on the 12 identified immune cell types, including naive B cells.
• Investigating drug sensitivity correlations for the 112 drugs mentioned, such as WZ3105.
• Exploring gene set enrichment for pathways like the melanoma pathway identified in the analysis.

Strengths

• Includes a constructed risk model based on six specific prognostic marker genes.
• Contains results from drug sensitivity analysis for 112 drugs.
• Integrates findings from single-cell and whole-genome transcriptomic analyses.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (11.9 KB), suggesting it contains summary or model results rather than raw data.

Provenance

Source

figshare, author Qi Zhao.

Collection Method

Likely contains integrated analysis results from single-cell and transcriptomic data.

Time Range

null

Freshness

Last updated 2026-04-13 05:21:47; freshness should be verified.

Geography

null